Skip to main content
Erschienen in: Clinical Rheumatology 4/2009

01.04.2009 | Original Article

The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis

verfasst von: Ingo H. Tarner, Ulf Müller-Ladner, Christine Uhlemann, Uwe Lange

Erschienen in: Clinical Rheumatology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Serial mild whole-body hyperthermia is a widely used balneotherapy modality for clinically inactive ankylosing spondylitis (AS) in rehabilitative medicine. Thus far, the mechanisms of its favorable influence on the symptoms of AS are not completely understood. We therefore analyzed the effect of mild whole-body hyperthermia on the systemic levels of pivotal proinflammatory cytokines. Twelve male subjects with AS and 12 healthy control subjects received nine cycles of whole-body hyperthermia (target body core temperature, 38.5°C; duration, 50 min). Serum samples were taken at the beginning of the last cycle and at 1, 6, and 24 h for measurement of tumor necrosis factor α, interleukin 1β and interleukin 6. Significant differences of cytokine levels were found between both groups. In AS patients, hyperthermia caused a significant reduction of all cytokines by 40–50%. Thus, serial mild whole-body hyperthermia in AS results in heat-induced changes of the proinflammatory cytokine network.
Literatur
1.
Zurück zum Zitat Panush RS (2000) American College of Rheumatology position statement: complementary and alternative therapies for rheumatic disease. Rheum Dis Clin North Am 26:189–192CrossRef Panush RS (2000) American College of Rheumatology position statement: complementary and alternative therapies for rheumatic disease. Rheum Dis Clin North Am 26:189–192CrossRef
2.
Zurück zum Zitat Hentschel HD, Nold F, Regehr I (1969) Beobachtungen bei der Überwärmungstherapie der ankylosierenden Spondylitis. Verh Dtsch Ges Rheumatol 1:184–188PubMed Hentschel HD, Nold F, Regehr I (1969) Beobachtungen bei der Überwärmungstherapie der ankylosierenden Spondylitis. Verh Dtsch Ges Rheumatol 1:184–188PubMed
3.
Zurück zum Zitat Bühring M, Bork-Wölwer L, Krippner H, Pirlet K (1977) Quantitative Veränderungen peripherer T-Lymphozyten unter Hyperthermie. MMW Münch Med Wochenschr 119:1591–1594PubMed Bühring M, Bork-Wölwer L, Krippner H, Pirlet K (1977) Quantitative Veränderungen peripherer T-Lymphozyten unter Hyperthermie. MMW Münch Med Wochenschr 119:1591–1594PubMed
4.
Zurück zum Zitat Bühring M, Bork-Wölwer L, Krippner H (1978) Peripheral T lymphocytopenia under exogenous thermal stress. Cancer 42:2794–2797PubMedCrossRef Bühring M, Bork-Wölwer L, Krippner H (1978) Peripheral T lymphocytopenia under exogenous thermal stress. Cancer 42:2794–2797PubMedCrossRef
5.
Zurück zum Zitat Schmidt KL (1987) Hyperthermie und Fieber. Wirkungen bei Mensch und Tier. Klinik, Pathologie, Immunologie, Wirkungen auf Entzündungen. Hippokrates Verlag, Stuttgart Schmidt KL (1987) Hyperthermie und Fieber. Wirkungen bei Mensch und Tier. Klinik, Pathologie, Immunologie, Wirkungen auf Entzündungen. Hippokrates Verlag, Stuttgart
6.
Zurück zum Zitat Schmidt KL, Simon E (2001) Thermotherapy of pain, trauma and inflammatory and degenerative rheumatic diseases. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 527–539 Schmidt KL, Simon E (2001) Thermotherapy of pain, trauma and inflammatory and degenerative rheumatic diseases. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 527–539
7.
Zurück zum Zitat Schmidt KL (2004) Zur Wirkung der Ganzkörperhyperthermie auf Entzündungen und Immunreaktionen: experimentelle Grundlagen. Phys Rehab Kur Med 14:1–9CrossRef Schmidt KL (2004) Zur Wirkung der Ganzkörperhyperthermie auf Entzündungen und Immunreaktionen: experimentelle Grundlagen. Phys Rehab Kur Med 14:1–9CrossRef
8.
Zurück zum Zitat Schleenbecker H, Schmidt KL (1998) Zur Wirkung einer iterativen milden Ganzkörper-Hyperthermie auf den Fibromyalgieschmerz. Phys Rehab Kur Med 8:113–117CrossRef Schleenbecker H, Schmidt KL (1998) Zur Wirkung einer iterativen milden Ganzkörper-Hyperthermie auf den Fibromyalgieschmerz. Phys Rehab Kur Med 8:113–117CrossRef
9.
Zurück zum Zitat Hori T, Kaizuka Y, Takaki A, Katafuchi T (2001) Thermal stress and immunity. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 242–251 Hori T, Kaizuka Y, Takaki A, Katafuchi T (2001) Thermal stress and immunity. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 242–251
10.
Zurück zum Zitat Lange U, Thielen G, Neeck G, Schmidt KL (2005) Einfluss der milden Hyperthermie auf die Blutspiegel von Kortisol und Lymphozytensubpopulationen bei Patienten mit ankylosierender Spondylitis und Gesunden. Phys Med Rehab Kuror 15:44–47CrossRef Lange U, Thielen G, Neeck G, Schmidt KL (2005) Einfluss der milden Hyperthermie auf die Blutspiegel von Kortisol und Lymphozytensubpopulationen bei Patienten mit ankylosierender Spondylitis und Gesunden. Phys Med Rehab Kuror 15:44–47CrossRef
11.
Zurück zum Zitat Braun J (2002) Stadiensystem radiographischer Einteilung. In: Braun J, Sieper J (eds) Spondylitis ankylosans. Uni-Med, Bremen, p 114 Braun J (2002) Stadiensystem radiographischer Einteilung. In: Braun J, Sieper J (eds) Spondylitis ankylosans. Uni-Med, Bremen, p 114
12.
Zurück zum Zitat Sobieska M, Stratz T, Samborski W et al (1993) Interleukin-6 (IL-6) after whole body cryotherapy and local hot mud pack treatment [letter]. Eur J Phys Med Rehabil 3:205 Sobieska M, Stratz T, Samborski W et al (1993) Interleukin-6 (IL-6) after whole body cryotherapy and local hot mud pack treatment [letter]. Eur J Phys Med Rehabil 3:205
13.
Zurück zum Zitat Olszewski WL, Grzelak I, Ziolkowska A, Engeset A (1989) Effect of local hyperthermia on lymph immune cells and lymphokines of normal human skin. J Surg Oncol 41:109–116PubMedCrossRef Olszewski WL, Grzelak I, Ziolkowska A, Engeset A (1989) Effect of local hyperthermia on lymph immune cells and lymphokines of normal human skin. J Surg Oncol 41:109–116PubMedCrossRef
14.
Zurück zum Zitat Bellometti S, Galzigna L (1998) Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Investig Med 46:140–145PubMed Bellometti S, Galzigna L (1998) Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Investig Med 46:140–145PubMed
15.
Zurück zum Zitat Yoshioka A, Miyachi Y, Imamura S et al (1989) Suppression of contact sensitivity by local hyperthermia treatment due to reduced Langerhans cell population in mice. Br J Dermatol 120:493–501PubMedCrossRef Yoshioka A, Miyachi Y, Imamura S et al (1989) Suppression of contact sensitivity by local hyperthermia treatment due to reduced Langerhans cell population in mice. Br J Dermatol 120:493–501PubMedCrossRef
16.
Zurück zum Zitat Huang YH, Haegerstrand A, Frostegård J (1996) Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol 103:61–66PubMedCrossRef Huang YH, Haegerstrand A, Frostegård J (1996) Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol 103:61–66PubMedCrossRef
17.
Zurück zum Zitat Shen RN, Hornback NB, Shidnia H et al (1991) Whole body hyperthermia: a potent radioprotector in vivo. Int J Radiat Oncol Biol Phys 20:525–530PubMed Shen RN, Hornback NB, Shidnia H et al (1991) Whole body hyperthermia: a potent radioprotector in vivo. Int J Radiat Oncol Biol Phys 20:525–530PubMed
18.
Zurück zum Zitat Tütüncü ZN, Turan M, Yüzbasioglu N, Karagülle MZ (1996) Changes in TNFα plasma levels in osteoarthritis patients under balneotherapy with acratothermal water. Phys Rehab Kur Med 6:80–82CrossRef Tütüncü ZN, Turan M, Yüzbasioglu N, Karagülle MZ (1996) Changes in TNFα plasma levels in osteoarthritis patients under balneotherapy with acratothermal water. Phys Rehab Kur Med 6:80–82CrossRef
19.
Zurück zum Zitat Tütüncü ZN, Bilgie A, Kennedy LG, Calin A (1994) Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425–426PubMedCrossRef Tütüncü ZN, Bilgie A, Kennedy LG, Calin A (1994) Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425–426PubMedCrossRef
20.
Zurück zum Zitat Gratacós J, Collado A, Filella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931PubMedCrossRef Gratacós J, Collado A, Filella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931PubMedCrossRef
21.
Zurück zum Zitat Falkenbach A, Herold M (1998) In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18:103–106PubMedCrossRef Falkenbach A, Herold M (1998) In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18:103–106PubMedCrossRef
22.
Zurück zum Zitat Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319–2324PubMedCrossRef Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319–2324PubMedCrossRef
23.
Zurück zum Zitat Bal A, Unlu E, Bahar G et al (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211–215PubMedCrossRef Bal A, Unlu E, Bahar G et al (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211–215PubMedCrossRef
24.
Zurück zum Zitat Park MC, Lee SW, Choi ST et al (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36:101–106PubMedCrossRef Park MC, Lee SW, Choi ST et al (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36:101–106PubMedCrossRef
25.
Zurück zum Zitat Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352PubMedCrossRef Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352PubMedCrossRef
26.
Zurück zum Zitat Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511PubMed Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511PubMed
27.
Zurück zum Zitat Chou CT, Huo AP, Chang HN et al (2007) Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res 38:190–195PubMedCrossRef Chou CT, Huo AP, Chang HN et al (2007) Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res 38:190–195PubMedCrossRef
28.
Zurück zum Zitat François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef
29.
Zurück zum Zitat Vazquez-Del MM, Garcia-Gonzalez A, Muñoz-Valle JF et al (2002) Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 29:522–526PubMed Vazquez-Del MM, Garcia-Gonzalez A, Muñoz-Valle JF et al (2002) Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 29:522–526PubMed
30.
Zurück zum Zitat Rudwaleit M, Siegert S, Yin Z et al (2001) Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 60:36–42PubMedCrossRef Rudwaleit M, Siegert S, Yin Z et al (2001) Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 60:36–42PubMedCrossRef
31.
Zurück zum Zitat Furst D, Breedveld FC, Kalden JR et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66(Suppl III):iii2–iii22PubMedCrossRef Furst D, Breedveld FC, Kalden JR et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66(Suppl III):iii2–iii22PubMedCrossRef
32.
Zurück zum Zitat Maini RN, Taylor PC, Szechinski J, CHARISMA Study Group et al (2006) Double-blind, randomized controlled trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829PubMedCrossRef Maini RN, Taylor PC, Szechinski J, CHARISMA Study Group et al (2006) Double-blind, randomized controlled trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829PubMedCrossRef
33.
Zurück zum Zitat Wendling D, Racadot E, Toussirot E, Wijdenes J (1996) Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 35:1330PubMedCrossRef Wendling D, Racadot E, Toussirot E, Wijdenes J (1996) Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 35:1330PubMedCrossRef
34.
Zurück zum Zitat Toussirot E, Lafforgue P, Boucraut J et al (1994) Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 13:175–180PubMedCrossRef Toussirot E, Lafforgue P, Boucraut J et al (1994) Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 13:175–180PubMedCrossRef
35.
Zurück zum Zitat Tan AL, Marzo-Ortega H, O’Connor P et al (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63:1041–1045PubMedCrossRef Tan AL, Marzo-Ortega H, O’Connor P et al (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63:1041–1045PubMedCrossRef
36.
Zurück zum Zitat Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64:296–298PubMedCrossRef Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64:296–298PubMedCrossRef
37.
Zurück zum Zitat Bennett AN, Tan AL, Coates LC et al (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology 47:223–224PubMedCrossRef Bennett AN, Tan AL, Coates LC et al (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology 47:223–224PubMedCrossRef
Metadaten
Titel
The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis
verfasst von
Ingo H. Tarner
Ulf Müller-Ladner
Christine Uhlemann
Uwe Lange
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 4/2009
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1059-x

Weitere Artikel der Ausgabe 4/2009

Clinical Rheumatology 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.